What drove last week’s volatile market

Wall Street got back to its winning ways last week after navigating a hawkish Federal Reserve meeting, volatile swings in chip stocks, and a critical round of Big Tech earnings. The Dow Jones Industrial Average rose 1% for the week, snapping a three-week losing streak. The S & P 500 gained 1% last week, while…

Read More

Here are 4 forces that drove a tough week for stocks

It was a tough week for stocks, as investors navigated everything from escalating tensions in the Middle East to key tech earnings reports to healthcare developments. Logging their second straight weekly losses, the S & P 500 slipped 0.6%, while the tech-heavy Nasdaq fell 2.1%. Here’s a closer look at what drove the trading action….

Read More

Market for psychedelic drugs to treat mental health gets a buy signal

Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health…

Read More

Eli Lilly, Regeneron in FDA PreCheck manufacturing program

Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s…

Read More